(0.27%) 5 145.25 points
(0.17%) 38 508 points
(0.38%) 17 914 points
(-0.14%) $83.73
(0.42%) $1.931
(0.12%) $2 350.10
(0.22%) $27.60
(1.93%) $939.90
(-0.15%) $0.933
(-0.34%) $10.99
(-0.31%) $0.798
(1.28%) $93.05
@ $17.66
发出时间: 15 Feb 2024 @ 03:01
回报率: -12.63%
上一信号: Feb 14 - 04:45
上一信号:
回报率: 3.03 %
Live Chart Being Loaded With Signals
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States...
Stats | |
---|---|
今日成交量 | 1.12M |
平均成交量 | 1.26M |
市值 | 2.20B |
EPS | $0 ( 2024-02-26 ) |
下一个收益日期 | ( $-0.670 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -14.56 |
ATR14 | $0.0230 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Sato Vicki L | Sell | 1 666 | Common Stock |
2024-04-01 | Krognes Steve E. | Sell | 92 500 | Common Stock |
2024-03-29 | Watts Ryan J. | Sell | 40 000 | Common Stock |
2024-03-15 | Sato Vicki L | Sell | 1 666 | Common Stock |
2024-02-15 | Sato Vicki L | Sell | 1 666 | Common Stock |
INSIDER POWER |
---|
33.10 |
Last 100 transactions |
Buy: 1 164 016 | Sell: 631 404 |
音量 相关性
Denali Therapeutics Inc 相关性 - 货币/商品
Denali Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $330.53M |
毛利润: | $313.81M (94.94 %) |
EPS: | $-1.060 |
FY | 2023 |
营收: | $330.53M |
毛利润: | $313.81M (94.94 %) |
EPS: | $-1.060 |
FY | 2022 |
营收: | $108.46M |
毛利润: | $101.43M (93.52 %) |
EPS: | $-2.60 |
FY | 2021 |
营收: | $48.66M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.40 |
Financial Reports:
No articles found.
Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。